Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma

gamma9delta2 T lymphocytes have been shown to be directly cytotoxic against renal carcinoma cells. Lymphocytes T gammadelta can be selectively expanded in vivo with BrHPP (IPH1101, Phosphostim) and interleukin 2 (IL-2). A phase I Study was conducted in patients with metastatic renal cell carcinoma (...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer immunology, immunotherapy : CII Vol. 57; no. 11; p. 1599
Main Authors:	Bennouna, Jaafar, Bompas, Emmanuelle, Neidhardt, Eve Marie, Rolland, Frédéric, Philip, Irène, Galéa, Céline, Salot, Samuel, Saiagh, Soraya, Audrain, Marie, Rimbert, Marie, Lafaye-de Micheaux, Sylvie, Tiollier, Jérôme, Négrier, Sylvie
Format:	Journal Article
Language:	English
Published:	Germany 01-11-2008
Subjects:	Adult Aged Antineoplastic Agents - therapeutic use Carcinoma, Renal Cell - immunology Carcinoma, Renal Cell - secondary Carcinoma, Renal Cell - therapy Combined Modality Therapy Disease Progression Female Humans Immunotherapy Interleukin-2 - therapeutic use Kidney Neoplasms - immunology Kidney Neoplasms - pathology Kidney Neoplasms - therapy Lymphocyte Count Lymphocytes, Tumor-Infiltrating - immunology Lymphocytes, Tumor-Infiltrating - pathology Male Maximum Tolerated Dose Middle Aged Prognosis Receptors, Antigen, T-Cell, gamma-delta - immunology Survival Rate T-Lymphocytes - immunology
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!